Scientific Publications
View relevant scientific publications for each of our core and non-core products
Setrusumab
- Glorieux F. et al. 2017. BPS-804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial., J Bone Miner Res, 32: 1496-1504.
- Shapiro J. 2017. Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease, Community Academic Press. Chapter 2: p15-22
Alvelestat
- Im A. et al. 2021. Effects of Alvelestat, an Oral Neutrophil Elastase Inhibitor, on Elevated Elastase and Collagen Turnover Biomarkers in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation. Blood: 138 (Sup 1): 1815
- Blanco I. et al. 2017. Alpha-1 Antitrypsin Pi*Z Gene Frequency And Pi*ZZ Genotype Numbers Worldwide: An Update, Int J COPD:12:561–569
- Blanco I. et al., 2017. Alpha-1 Antitrypsin Pi*SZ Genotype: Estimated Prevalence And Number Of SZ Subjects Worldwide, Int J COPD:12:1683–1694
- Stockley R. et al. 2013, Phase II Study Of A Neutrophil Elastase Inhibitor (AZD9668) In Patients With Bronchiectasis, Respir Med:107(4):524-533
- Rodriguez-Frias et al. 2012. Rare Alpha-1-antitrypsin Variants: Are They Really So Rare? Ther Adv Respir Dis: 6:79-84
- Vogelmeier C. et al. 2012. A Randomised, Placebo-controlled, Dose-finding Study Of AZD9668, An Oral Inhibitor Of Neutrophil Elastase, In Patients With Chronic Obstructive Pulmonary Disease Treated With Tiotropium. COPD:9 (2):111-120
- Elborn JS et al. 2012. Efficacy, Safety And Effect On Biomarkers Of AZD9668 In Cystic Fibrosis. Eur Respir J:40(4):969-976
- Silverman E. & Sandhaus R. 2009. Alpha1-Antitrypsin Deficiency. NEJM 360: 2749-2757
- R. A. Stockley et al 2023. Alvelestat, an Oral Neutrophil Elastase Inhibitor in Alpha-1 Antitrypsin Deficiency (AATD): Results of a Phase II Trial. American Thoracic Society (oral presentation)
- J. Parkin et al 2023. Analysis From Phase II Clinical Trial, Alvelestat, NE (Neutrophil Elastase) Inhibitor in AATD-LD: Correlation Between Biomarker Response (Desmosine and Aa-val360) and Clinical Outcome (SGRQ). American Thoracic Society (poster)
Etigilimab
- Sarikonda G. et al. 2022. Interim biomarker analysis of a Phase 1b/2 Study of anti-TIGIT Etigilimab (MPH313) and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE), ESMO, (poster)
- McKean M. et al. 2022. Safety and Efficacy of Etigilimab in Combination with Nivolumab in Select Recurrent/Advanced Solid Tumors, ASCO, (poster)
- McKean M. et al. 2022. Safety and Efficacy of Etigilimab in Combination with Nivolumab in Select Recurrent/Advanced Solid Tumors, Jour Clin Onc:40:16_suppl, 2651-2651
- Mettu N. et al. 2021. A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors, Clin Cancer Res: 28 (5): 882–892.
- Dolgin E. 2020. Antibody engineers seek optimal drug targeting TIGIT checkpoint, Nat Biotechnol, (poster)
- Huang Y. et al. 2019. Interim biomarker analysis etigilimab MPH-313 anti-TIGIT antibody advanced solid tumors supports TIGIT associated MOA, Keystone (poster)
- Sharma S. et al. 2018. Initial results from a phase 1a/b study of Etigilimab (MPH-313), an anti-T cell immunoreceptor with Ig and ITIM domains (TIGIT) antibody in advanced solid tumors, SITC, (poster)
- Argast G. et al. 2018. Anti-TIGIT biomarker study: Inhibition of TIGIT induces loss of T regs from tumors and requires effector function for tumor growth inhibition, AACR, (poster)
- Cattaruzza F. et al. 2017. Pharmacodynamic biomarkers for anti-TIGIT treatment and prevalence of TIGIT expression in multiple solid tumor types, AACR, (poster)
- Srivastava M. et al. 2017. Anti-TIGIT induces T cell-mediated anti-tumor immune responses and combines with immune checkpoint inhibitors to enhance strong and long term anti-tumor immunity, AACR, (poster)
- Park A et al. 2017. Antibody against T cell Immunoreceptor with Ig and ITIM domains (TIGIT) Induces anti-Tumor Immune Response and Generates Long-Term Immune Memory, AACR, (poster)